Brief: EMA's CHMP Recommends Extensions Of Indication For Bexsero & Talzenna
BRIEF-EMA's CHMP Recommends Extensions Of Indication For Bexsero & Talzenna Nov 13 (Reuters) - EMA's CHMP:
EMA'S CHMP: RECOMMENDED EXTENDING USE OF GAZYVARO (OBINUTUZUMAB) TO TREAT ADULTS WITH MODERATE-TO-SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
EMA'S CHMP: RECOMMENDS GRANTING MARKETING AUTHORISATION FOR BAXFENDY
EMA'S CHMP: RECOMMENDED EXTENSIONS OF INDICATION FOR BEXSERO, COSENTYX, DOVATO, ENFLONSIA, STEGLATRO, SUNLENCA, TALZENNA, TIVICAY, WELIREG
EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR TALZENNA
EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR STEGLATRO
EMA'S CHMP: ADOPTED DHPC ABOUT POTENTIAL EFFECT OF MOUNJARO (TIRZEPATIDE) ON RELIABILITY OF ORAL CONTRACEPTIVES
EMA'S CHMP: DHPC REMINDS HEALTHCARE PROFESSIONALS THAT CONTRACEPTION IS RECOMMENDED FOR WOMEN WHO CAN BECOME PREGNANT & USING MOUNJARO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eli Lilly and
See all newsBiogen's anti-tau Alzheimer's drug benefits increase at 2 years
Eli Lilly’s $1.4 trln valuation is heavy with hope
Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion (updated)
Brief: Stipple Bio Enters Multi-Target Oncology Collaboration With Eli Lilly
Deals of the day-Mergers and acquisitions